

You Are Cordially Invited to Attend a Professional Lecture

This promotional program is intended to educate healthcare practitioners on

TREATMENT OPTIONS FOR IBS-D AND FOR IBS-C AND CIC: A CLINICAL REVIEW



Featuring

Filippo Cremonini, MD

Gastroenterologist, Las Vegas Gastroenterolog

Tuesday, February 13, 2018 6:30PM

Nora's Italian Cuisine

5780 West Flamingo Road, Las Vegas, NV 89103, 702-873-8990

Please RSVP by Friday, Feb 02, 2018

RSVP to www.Allerganrsvp.com or by calling 877-994-6872. Please reference PRF1327493

For questions, contact your Allergan representative, Geoff Robinson

Email: GEOFF.ROBINSON@ALLERGAN.COM Mobile: 702-280-1453

This promotional event is brought to you by Allergan and is not certified for continuing medical education. The speaker is a paid consultant presenting on behalf of Allergan and the information being presented is consistent with FDA guidelines. This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. It is Allergan's policy to include only those healthcare professionals involved in patient care consistent with our product indication(s).

The cost of meals and refreshments provided to U.S. HCPs may be subject to public disclosure. Allergan's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. Allergan abides by applicable federal and state laws which prohibit or limit the ability of government employees and certain healthcare professionals to accept items of value from Allergan. Please comply with applicable law. Attendance might be limited to Company policy on product indication and promotion.

INDICATIONS AND USAGE

VIBERZI (eluxadoline) is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

IMPORTANT SAFETY INFORMATION FOR VIBERZI

Contraindications

VIBERZI is contraindicated in patients:

- Without a gallbladder.
- With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction; a history of pancreatitis; or structural diseases of the pancreas.
- With alcoholism, alcohol abuse, alcohol addiction, or who drink more than 3 alcoholic beverages per day.
- With severe hepatic impairment.
- With a history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.

INDICATIONS AND USAGE

LINZESS (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

IMPORTANT SAFETY INFORMATION FOR LINZESS

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
LINZESS is contraindicated in patients less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. Use of LINZESS should be avoided in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS have not been established in patients less than 18 years of age.

Please see additional Important Safety Information for VIBERZI and LINZESS on reverse and accompanying full Prescribing Information.